ArticleLancet regional health. Americas2023
The impact of immigration on hepatitis B burden in the United States: a modelling study.
Article in Lancet regional health. Americas, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Disparities in hepatitis B virus healthcare service access among marginalised poor populations: a mixed-method systematic review.Infectious diseases of poverty · 2024Pooled it
- Genetic Diversity, Occult Hepatitis B, and Mutational Signatures in Migrants from Regions with Varying HBV Endemicity: Importation of Diverse Viral Variants into St. Petersburg, Russia.International journal of molecular sciences · 2026Article
- From screening to care: a longitudinal implementation evaluation of a community-based hepatitis B program.BMC public health · 2026Article
- Chronic Viral Hepatitis Screening Inequities Across Florida Federally Qualified Health Centers.Journal of racial and ethnic health disparities · 2026Article
- Gaps and Disparities in the Hepatitis B Cascade of Care Among a National Cohort of US Veterans With Chronic Hepatitis B Infection.Clinical and translational gastroenterology · 2026Article
- Dissecting incidence and mortality inequalities of six types of liver diseases in 39 alcohol-dominant countries and 93 virus-dominant countries under the aging context: Insights from the Global Burden of Disease Study 2021.Translational oncology · 2026Article
- The Current Burden of Hepatitis B in the United States: A State, Territorial, and County Modelling Analysis.Journal of viral hepatitis · 2026Article
- Global burden, trends and inequalities of hepatitis B among women of childbearing age, 1990-2021.Annals of medicine · 2025Article
- Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021.Hepatology (Baltimore, Md.) · 2025Article
- Intrahepatic cholangiocarcinoma mortality in the USA, 1999-2020: a 21-year population-based analysis.Cancer causes & control : CCC · 2025Article
- Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study.The Lancet regional health. Europe · 2025Article
- Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign-Born: The FOCUS-HBV Multicentre Cohort.Alimentary pharmacology & therapeutics · 2025Article
- Trends in viral hepatitis-related mortality in the United States from 1999 to 2022: A retrospective study.World journal of hepatology · 2025Article
- The Management of Chronic Hepatitis B: 2025 Guidelines Update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada.Canadian liver journal · 2025Article
- Vaccination Status and Influencing Factors of Delayed Vaccination in Toddlers Born to Hepatitis B Surface Antigen-Positive Mothers.Vaccines · 2025Article
- Decreasing hepatitis B seroprevalence in pregnant women in Taiwan between 2016 and 2021: a claim-based cohort study.BMC public health · 2025Article
- Chronic Hepatitis B Costs and Healthcare Resource Utilization in a Japanese Patient Population: A Retrospective Cross-Sectional Analysis.Digestive diseases (Basel, Switzerland) · 2025Article
- Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances.World journal of hepatology · 2024Article
- The economic argument for hepatitis B treatment simplification and expansion.Journal of viral hepatitis · 2024Review
- Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States.Journal of viral hepatitis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infections by 2030. However, the HBV prevalence in Western countries, where the historical prevalence is low and highly impacted by immigration trends, remains uncertain making planning difficult. We aimed to develop a more accurate estimate of HBV prevalence and identify key immigrant populations that need to be screened, vaccinated, and treated to achieve the elimination targets. Methods: US immigration data from 1900 forward and country-specific modeled prevalence by age and sex were used to estimate immigrated HBV infections entering the US, new infections in the US, mortality (all-cause and liver-related), and disease burden through 2030. Findings: Using a dynamic Markov model, we estimated 1.8 million (95% uncertainty interval: 1.3-2.6 million) HBV infections in 2020 in all ages, higher than the NHANES national serosurvey. Infections between ages 30-74 accounted for 82% of all cases. Furthermore, HBV infections were concentrated among immigrants. New decompensated cirrhosis, hepatocellular carcinoma, and liver related deaths are expected to increase by 20%, 31% and 25% respectively from 2019 to 2030 at current diagnosis and treatment rate. Interpretation: National serosurveys can underestimate total infections due to under-sampling in immigrant populations. To meet the WHO elimination targets, culturally appropriate screening and linkage to care programs in the immigrant populations are needed in the US. In their absence, there will be significant increases in the burden of HBV and the US will fail to meet the elimination targets by 2030. Funding: This analysis was funded by a research grant from Gilead Sciences (IN-US-988-5786) and made possible by grants from John C Martin Foundation (2019-G024), ZeShan Foundation (2021-0101-1-CDA-HEP-10), and EndHep2030 who supported country analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.